Gilead Sciences (GILD): CFO sold ~$284K
Andrew D Dickinson, CFO at Gilead Sciences, sold ~$284K of Gilead Sciences shares.
- ~$284K
- Approx. value · 2,500 sh @ $113.57
- 160K
- Holds after · shares reported
- Traded
- Sep 15, 2025
- Filed
- Sep 16, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 29, 2024CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Jul 28, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
- Jul 30, 2025FDAFDA drug approval: Biktarvy
- Aug 6, 2025Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 5 employees
- Aug 15, 2025Insider · 2 peopleInsiders: 7 sales (~$3.6M)
- Aug 28, 2025InsiderCEO sold ~$1.14M of GILD shares in the open market
- Sep 15, 2025 · this disclosureInsiderCFO sold ~$284K of GILD shares in the open market
What came next
- Sep 15, 2025InsiderOfficer sold ~$341K of GILD shares in the open market
- Sep 23, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
- Sep 29, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
- Oct 15, 2025Insider · 2 peopleInsiders: 2 sales (~$649K)
- Oct 28, 2025Insider · 1 personInsiders: 2 sales (~$1.2M)
- Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 12, 2025Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 17 employees
- Nov 12, 2025Insider · 1 personInsiders: 3 sales (~$6.6M)
- Nov 15, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025.”
- Nov 17, 2025Insider · 2 peopleInsiders: 3 sales (~$3.8M)
- Nov 26, 2025InsiderDirector sold ~$357K of GILD shares in the open market
- Nov 28, 2025Insider · 3 peopleInsiders: 4 sales (~$2.2M)
- Dec 12, 2025Government · Federal Register noticeDetermination That DEMEROL (Meperidine Hydrochloride) Tablet, 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Dec 15, 2025Insider · 2 peopleInsiders: 2 sales (~$732K)
- Dec 29, 2025InsiderCEO sold ~$1.25M of GILD shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Gilead Sciences
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.
Other recent filings by Andrew D Dickinson, Chief Financial Officer
- SEC Form 4 at Gilead Sciences (GILD)Nov 18, 2026
- SEC Form 4 at Gilead Sciences (GILD)Oct 16, 2026
- SEC Form 4 at Gilead Sciences (GILD)Sep 16, 2026
- SEC Form 4 at Gilead Sciences (GILD)Aug 18, 2026
- SEC Form 4 at Gilead Sciences (GILD)Jul 16, 2026
The full history of Andrew D Dickinson, Chief Financial Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Gilead Sciences (GILD) insider traded, and how much?
Andrew D Dickinson, CFO at Gilead Sciences, sold ~$284K of Gilead Sciences shares. 2,500 shares at $113.57.
When did it happen, and when was it made public?
Traded: Sep 15, 2025. Filed: Sep 16, 2025. That is 1 day between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Gilead Sciences recently?
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.
Does this mean GILD stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Gilead Sciences
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 16, 2026
Everything OQRO holds on this company is on its GILD page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
